Immunitas Therapeutics to Present Clinical Data Supporting Monotherapy and Combination Treatment Potential of IMT-009 at the AACR 2026 Annual Meeting March 18, 2026
Immunitas Therapeutics Presents Preclinical Data on IMT-380, a First-in-Class Anti-CD161 Antibody, at FASEB Science Research Conference on Autoimmunity July 31, 2025
Immunitas Therapeutics Presents Preclinical Data Supporting Combination of IMT-009 with Anti-PD1 Immunotherapy at the AACR April 9, 2024
Immunitas Therapeutics to Present Preclinical Data Supporting Combination of IMT-009 with Anti-PD1 Immunotherapy at AACR March 7, 2024
Immunitas Therapeutics Announces Appointment of James Wooldridge as Chief Medical Officer and Upcoming Presentation at ASH 2023 Annual Meeting December 5, 2023
